No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

We recently compiled a list of the These 10 Companies Led Gains on Wednesday. In this article, we are going to take a look at ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.